I watched a webinar presented by Verici DX (VRCI) this morning on the Investor Meet Company platform. This is an early-stage biotech company who specialise in transplant rejection diagnosis. They do have some revenue but are still loss making. They have done a recent fund raising which at least means they won’t run out of cash in the near future.
As a kidney transplant patient of over 20 years standing I do well understand the importance of picking up rejection episodes quickly so that treatment can be executed promptly. I only acquired a few shares in the company as a free spin-off from another holding. But will the company really generate profits in the long-term? I think it’s too early to tell so I am unlikely to invest more in the business until that becomes clearer.
Roger Lawson (Twitter: https://x.com/RogerWLawson )
You can obtain notifications of new posts in future by following me on Twitter (now “X”) – see https://x.com/RogerWLawson where new blog posts are usually mentioned.